Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of…mehr
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications. This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types. Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
Renal Medicine and Hypertension Section, Division of General Internal Medicine
University of Colorado School of Medicine and
Director, Home Dialysis Program
University of Colorado Hospital
Aurora, CO 80045
isaac.teitelbaum@cuanschutz.edu
Bonita A. Simendinger, PharmD, BCPS
P&T Formulary Compliance Specialist
University of Colorado Hospital
Aurora, CO 80045
bonita.simendinger@uchealth.org
Tyree H. Kiser, PharmD, BCPS, FCCP, FCCM
Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and
Critical Care Pharmacy Specialist
University of Colorado Hospital
Aurora, CO 80045
ty.kiser@cuanschutz.edu
Gerard R. Barber, RPh, MPH, FASHP
Clinical Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, CO 80045
gerard.barber@cuanschutz.edu
Nancy M. Stolpman, PharmD, PhD
Associate Clinical Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and
Lead Director of Pharmacy
UCHealth
Aurora, CO 80045
nancy.stolpman@uchealth.org
Inhaltsangabe
A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.- : Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.
A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.- : Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.
A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.- : Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.
A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.- : Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/neu